Developments in Scanning Electron Microscopy for Tablet and Granule Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developments in Scanning Electron Microscopy for Tablet and Granule Characterization
Recent advances in SEM, particularly the incorporation of automation and software, have made simpler, lower-end SEM instruments easy to operate and have improved the capabilities of larger, sophisticated instruments.


Pharmaceutical Technology


To provide the resolution necessary to generate images that can be statistically analyzed, FEI had to modify its detectors. "The high energy primary electron beam causes low energy (secondary) electrons to emerge from the specimen and are then accelerate (pulled) toward the detector," says Ben Lich, strategic marketing manager of SEM and DualBeam at FEI. Using a standard secondary electron detector the particles in the image appear to be illuminated from one side only, resulting in a dark and a bright side. The company engineers created a special symmetrical secondary electron detector that eliminates this effect. "But when you do that, normally you will get a dark side of the object and a bright side of the object, with the bright side being the side facing," says Lich. "For particle detection this is not desired because you want a good impression of the outer area of the particle so you can do a precise measurement." Engineers then made a special detector that collects a secondary electron symmetrically around the column and around the primary beam, thereby providing uniform illumination of the entire specimen surface and a good definition of the edge around the entire particle.

The advances in SEM instrumentation are making it easier for tablet manufacturers looking into adding SEM instrumentation to their quality laboratories. "With a low-entry type of tool, people get exposed to electron microscopy and may then follow with a higher-end instrument," says Lich. "They find that it is not as hard as some people think it is."

References

1. All You Wanted to Know about Electron Microscopy (FEI Company, Hillsboro, OR).

2. D.A. Muller et al., "Atomic-Scale Chemical Imaging of Composition and Bonding by Aberration-Corrected Microscopy," Science 319 (5866), 1073–1076 (2008).

3. Advances in Optical Imaging (D0D2) and Emerging Technologies in Microscopy (D353) (Frost & Sullivan, http://www.frost.com/).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here